This invention belongs to the field of
biomedicine and provides the application of LAPF and its agonists in the preparation of drugs for the treatment or prevention of
postherpetic neuralgia. This invention targets spinal
microglia by administering LAPF
protein, a
gene vector encoding LAPF, or an upregulator of their expression / activity, restoring their antiviral immune function, inhibiting
neuroinflammation, and promoting the expression of
neuroprotective factors. Animal experimental results show that administering LAPF
protein, a
gene vector encoding LAPF, or an upregulator of their expression / activity can significantly reduce mechanical
hyperalgesia, decrease HSV-1 / VZV-related nerve damage, and effectively alleviate symptoms of chronic
neuralgia.